Phospholipid profile of developing heart of rats exposed to low-protein diet in pregnancy.
Although the myocardial phospholipid and fatty acid content have profound effects on the heart function, very little information is available on the effects of restricted maternal protein intake during pregnancy on the phospholipid profile and fatty acid content of the developing heart. The present study was therefore undertaken to examine the effect of pregnant dams fed diets containing either 180 (normal) or 90 (low) g/kg casein diet for 2 wk before mating and throughout pregnancy on myocardial phospholipid and fatty acid content of male offspring. Whereas no changes in phosphatidylcholine and phosphatidylethanolamine were detected, increases in lysophosphatidylcholine, phosphatidylserine, and sphingomyelin were seen in the hearts of offspring in the low-protein (LP) group. Analysis of cardiac fatty acids revealed that although the saturated fatty acid (myristate, palmitate, and stearate) levels were significantly reduced, the unsaturated fatty acid (linoleate, arachidonate, and decosahexanoate) levels were significantly increased in the developing heart in the LP group. Furthermore, assessment of nuclear transcription factors involved in regulation of cardiac metabolism revealed a decrease in myocyte enhancer factor-2C mRNA levels in the LP group, whereas an increase in the mRNA amount of peroxisome proliferator-activated receptor-alpha was observed in this group. These results demonstrate that maternal LP diet can induce changes in the phospholipid profile and fatty acid content of the developing heart, which may have implications for metabolism of the neonatal heart.
Tappia
Paramjit S
PS
Cardiac Membrane Biology Laboratory, Institute of Cardiovascular Sciences, St. Boniface Hospital Research Centre (R3020), 351 Tache Ave., Winnipeg, Manitoba, Canada R2H 2A6. ptappia@sbrc.ca
Nijjar
Mohinder S
MS
Mahay
Aric
A
Aroutiounova
Nina
N
Dhalla
Naranjan S
NS
D000818:Animals; D018753:Diet, Protein-Restricted; D004734:Energy Metabolism / Q000187:drug effects; D005227:Fatty Acids / Q000378:metabolism; D005231:Fatty Acids, Unsaturated / Q000378:metabolism; D005260:Female; D008244:Lysophosphatidylcholines / Q000032:analysis; D009206:Myocardium / Q000378:metabolism*; D010718:Phosphatidylserines / Q000032:analysis; D010743:Phospholipids / Q000032:analysis*; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D013109:Sphingomyelins / Q000032:analysis
D005227:Fatty Acids; D005231:Fatty Acids, Unsaturated; D008244:Lysophosphatidylcholines; D010718:Phosphatidylserines; D010743:Phospholipids; D013109:Sphingomyelins